Maxcyte (MXCT) Depreciation & Amortization (CF) (2020 - 2026)

Maxcyte has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 1.42% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.3 million through Dec 2025, up 0.58% year-over-year, with the annual reading at $4.3 million for FY2025, 0.58% up from the prior year.
  • Depreciation & Amortization (CF) was $1.1 million for Q4 2025 at Maxcyte, roughly flat from $1.1 million in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $1.1 million in Q1 2024 and troughed at $315900.0 in Q1 2021.
  • The 5-year median for Depreciation & Amortization (CF) is $1.0 million (2023), against an average of $847360.0.
  • Year-over-year, Depreciation & Amortization (CF) soared 120.82% in 2022 and then fell 4.08% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $416500.0 in 2021, then soared by 120.82% to $919700.0 in 2022, then rose by 19.82% to $1.1 million in 2023, then decreased by 4.08% to $1.1 million in 2024, then grew by 1.42% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Depreciation & Amortization (CF) are $1.1 million (Q4 2025), $1.1 million (Q3 2025), and $1.1 million (Q2 2025).